

**International  
Comparative  
Legal Guides**



# **Drug & Medical Device Litigation**

# **2024**

**Fifth Edition**

Contributing Editor:

**Adrienne Franco Busby**  
Faegre Drinker Biddle & Reath LLP

**glg** Global Legal Group

## Expert Analysis Chapters

- 1** **Expert Witness Practice in U.S. Drug and Medical Device Litigation**  
Adrienne Franco Busby & Eric M. Friedman, Faegre Drinker Biddle & Reath LLP
- 11** **Legal Impact Analysis: Strategic and Sustainable Management in Drug & Medical Device Litigation in Italy**  
Sonia Selletti, Annalisa Scalia, Roberta Beretta & Sara Bravi, Astolfi e Associati Studio Legale

## Q&A Chapters

- 18** **Australia**  
Clayton Utz: Greg Williams, Alexandra Rose & Ethan Tindall
- 27** **Chile**  
Carey: Ignacio Gillmore Valenzuela, Mónica Pérez Quintana, Camila Suárez Alcántara & Javier Salgado Alonso
- 35** **Ecuador**  
Flor Bustamante Pizarro Hurtado: Gilberto Alfonso Gutiérrez Perdomo
- 44** **England & Wales**  
Mills & Reeve: Isabel Teare, Stephanie Caird, Mark Davison & Rebecca Auster
- 52** **France**  
Signature Litigation: Sylvie Gallage-Alwis, Alice Decramer & Nikita Yahouedeou
- 61** **Germany**  
Preu Bohlig & Partner Rechtsanwälte mbB: Peter von Czetztritz, Tanja Strelow & Dr. Stephanie Thewes
- 69** **Greece**  
KLC Law Firm: Theodore Loukopoulos, Georgia Stavropoulou & Zoe Syrmakezi
- 77** **Hong Kong**  
Deacons: Paul Kwan & Mandy Pang
- 85** **India**  
LexOrbis: Manisha Singh & Varun Sharma
- 95** **Japan**  
TMI Associates: Sayaka Ueno & Yuto Noro
- 103** **Norway**  
Advokatfirmaet GjessingReimers AS: Yngve Øyehaug Opsvik & Felix Reimers
- 111** **Singapore**  
Allen & Gledhill: Tham Hsu Hsien & Koh En Ying
- 121** **Spain**  
Faus Moliner: Xavier Moliner & Juan Martínez
- 134** **Sweden**  
Setterwalls Advokatbyrå: Helena Nilsson, Lovisa Dahl Nelson, Johan Montan & Jonatan Blomqvist
- 142** **Switzerland**  
Wenger Plattner: Dr. Tobias Meili, Dr. Carlo Conti & André S. Berne
- 151** **Taiwan**  
Formosan Brothers Attorneys-at-Law: Yvonne Y.F. Lin, Jessie C.Y. Lee & Yowlun Su
- 159** **USA**  
Faegre Drinker Biddle & Reath LLP: Joe Winebrenner, Eldin Hasic & Christine R. M. Kain

# Australia



Greg Williams



Alexandra Rose



Ethan Tindall

Clayton Utz

## 1 Regulatory Framework

**1.1 Please list and describe the principal legislative and regulatory bodies that apply to and/or regulate pharmaceuticals, medical devices, supplements, over-the-counter products, and cosmetics.**

The Therapeutic Goods Administration (**TGA**) is the regulatory agency responsible for therapeutic goods in Australia. Therapeutic goods are broadly defined under the *Therapeutic Goods Act 1989* (Cth) (**TG Act**) as products for use in humans in connection with: preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury; influencing, inhibiting or modifying a physiological process; testing susceptibility to disease; influencing, controlling or preventing conception; testing for pregnancy; or replacing or modifying an anatomical part. Therapeutic goods include medicines (including prescription, over-the-counter and complementary medicines), biologicals, supplements, vaccines and medical devices. The TG Act requires most therapeutic goods to be registered on the Australian Register of Therapeutic Goods (**ARTG**) before they can be promoted or supplied in Australia. The TG Act is supported by the *Therapeutic Goods Regulations 1990* (Cth) (**TG Regulations**), the *Therapeutic Goods (Medical Devices) Regulations 2002* (Cth), and various other regulations, orders and determinations.

Cosmetics are only regulated by the TGA if therapeutic claims are made. Otherwise, the chemical ingredients in cosmetics are regulated as industrial chemicals under the *Industrial Chemicals Act 2019* (Cth), which is administered by the Australian Industrial Chemicals Introduction Scheme.

**1.2 How do regulations/legislation impact liability for injuries suffered as a result of product use, or other liability arising out of the marketing and sale of the product? Does approval of a product by the regulators provide any protection from liability?**

Australia has a largely statutory product liability regime, found within the Australian Consumer Law (**ACL**). In *Peterson v Merck Sharp & Dohme (Australia) Pty Ltd* (2010) 184 FCR 1 (**Vioxx**), the Federal Court of Australia considered whether the TGA's approval of the anti-arthritis prescription medicine Vioxx provided the

companies with any protection from liability. In that decision, the Court found that compliance with the TGA requirements was not sufficient to discharge a company's duty of care, and found no basis in the TG Act to support such an argument. The Court was also hesitant to accept compliance with the TGA approval system as a relevant factor in determining whether a company had discharged its duty of care, since to do so would mean that a manufacturer could never be held to have fallen short in the discharge of its duty of care. Approval was also not a sufficient defence to statutory claims under the former *Trade Practices Act* (the precursor to the ACL), which relates to misleading and deceptive conduct and the requirement that consumer goods be fit for purpose and of merchantable quality. In short, Australia does not recognise a U.S.-style defence of pre-emption.

**1.3 What other general impact does the regulation of life sciences products have on litigation involving such products?**

While statutory approval is not a complete defence to litigation, it is relevant to the standard of care and to an assessment of a safety defect or whether a product is of acceptable quality. Under the Australian statutory product liability regime, a product cannot be defective purely because of its compliance with a mandatory standard. Therefore, to the extent that the regulations impose specific requirements, compliance with these requirements cannot found an allegation of defect. However, regulatory action in relation to a life sciences product (for example, a recall or a field safety action) may be a trigger for plaintiff lawyers to investigate and potentially commence litigation. Further, in the past, Parliamentary reviews of the TG Regulations have played an important part in product liability litigation; for example, in the transvaginal mesh litigation and the ASR prosthetic hip litigation.

**1.4 Are there any self-regulatory bodies that govern drugs, medical devices, supplements, OTC products, or cosmetics in the jurisdiction? How do their codes of conduct or other guidelines affect litigation and liability?**

Self-regulation of promotional activities is a critical part of the Australian regulatory regime. Several industry bodies have

developed codes and guidelines that regulate the manner in which their members may promote their products and interact with healthcare practitioners and the general public. Industry peak bodies that have such codes include:

- Medicines Australia: the Medicines Australia Code of Conduct (**MACC**) in respect of prescription medicines;
- the Medical Technology Association of Australia: the Medical Technology Industry Code of Practice (**MTIC**) in respect of medical devices;
- the Generic and Biosimilar Medicines Association (**GBMA**): the GBMA Code of Practice in respect of generic medicines; and
- Pathology Technology Australia in respect of *in vitro* diagnostic (**IVD**) devices: the Pathology Technology Industry Code of Practice.

#### 1.5 Are life sciences companies required to provide warnings of the risks of their products directly to the consumer, or to the prescribing physician (i.e., learned intermediary), and how do such requirements affect litigation concerning the product?

Yes. At common law, life sciences companies are required to take reasonable steps to ensure that consumers are warned of foreseeable risks associated with the use of their products. Failure to do so may lead to a claim of negligence against the company. A failure to warn consumers that a product has a defect, is of unacceptable quality or is otherwise unfit for purpose may result in a claim against the company pursuant to the ACL. There is no express authority for the learned intermediary principle, and it has not been widely considered. The defence was raised before the Court at first instance in *Vioxx* (see question 1.2), which was unwilling to apply it as it considered the defence too categorical an articulation of the duty of a therapeutic good manufacturer. The Court opined that the defence assumed that a physician is best equipped to receive a warning from the drug supplier and does not contemplate other situations in which a manufacturer's duty to take reasonable care may not be sufficiently discharged. In considering the appeal in the vaginal mesh litigation (*Ethicon Sàrl v Gill* [2021] FCAFC 29), the Full Federal Court of Australia held that in assessing whether a product was defective for the purposes of the ACL and for claims in negligence, the relevant question was whether a manufacturer of the device will furnish doctors with sufficient information, advice and warnings to permit a balanced, cautious and informed judgment to be made by the doctor and an informed choice by the patient.

## 2 Manufacturing

#### 2.1 What are the local licensing requirements for life sciences manufacturers?

Australian manufacturers of therapeutic goods other than medical devices must hold a manufacturing licence issued by the TGA, as well as a wholesaler's licence issued by the Department of Health of the state or territory where their manufacturing premises are located.

Before therapeutic goods manufactured overseas can be sold in Australia, their manufacturers must obtain either a Good Manufacturing Practice (**GMP**) clearance or a GMP certification from the TGA. A GMP clearance typically applies where there are mutual recognition arrangements with the manufacturer's local regulator.

Australian and overseas manufacturers of medical devices must hold evidence that a device has undergone an appropriate

conformity assessment procedure before it can be included in the ARTG. For devices that contain medicines or materials of animal, microbial, recombinant or human origin, and Class 4 IVDs, the TGA will accept conformity assessment evidence issued by the TGA, EU notified bodies and Australian Conformity Assessment Bodies.

#### 2.2 What agreements do local regulators have with foreign regulators (e.g., with the U.S. Food and Drug Administration or the European Medicines Agency) that relate to the inspection and approval of manufacturing facilities?

The TGA has various international agreements and arrangements with foreign regulatory authorities. Some of these allow member countries to rely on each other's GMP inspection programmes, including many of the medicines regulatory authorities of the EU Member States and the U.S. FDA under the Pharmaceutical Inspection Cooperation Scheme. There are also information-sharing agreements in place with other major international regulators.

#### 2.3 What is the impact of manufacturing requirements or violations thereof on liability and litigation?

In an action under the ACL relating to a safety defect, a manufacturer can claim in its defence that the defect only existed because the manufacturer had complied with a mandatory standard pursuant to section 142(b) of the ACL. If this defence is made out, the Commonwealth may have to compensate the claimant.

If a manufacturer fails to comply with manufacturing requirements, it could give rise to liability under the ACL and common law.

## 3 Transactions

#### 3.1 Please identify and describe any approvals required from local regulators for life sciences mergers/acquisitions.

Life sciences companies are subject to the same laws regulating mergers and acquisitions as other industries in Australia. There are no additional approval requirements for life sciences products.

#### 3.2 What, if any, restrictions does the jurisdiction place on foreign ownership of life sciences companies or manufacturing facilities? How do such restrictions affect liability for injuries caused by use of a life sciences product?

The Foreign Investment Review Board (**FIRB**) regulates foreign investment in Australia. The FIRB regime applies to "foreign persons", including corporations, looking to invest in Australian land or entities, including life sciences companies and manufacturing facilities. The Treasurer may prohibit a foreign investment in a life sciences company if it would be contrary to the national interest. The Treasurer may also apply conditions to safeguard national interests. The FIRB regime also imposes civil and criminal penalties for proceeding with a transaction that is a "significant action" or a "notifiable action", unless and until the FIRB provides a statement of no objection. Foreign persons proposing to invest in a manufacturer of essential medicines or medical devices are encouraged by the FIRB to voluntarily seek foreign investment approval. Essential medicines include



those that are listed in the Pharmaceutical Benefits Scheme (PBS), and essential medical devices include the manufacture of personal protective equipment and diagnostic equipment, pacemakers and prosthetics.

## 4 Advertising, Promotion and Sales

**4.1 Please identify and describe the principal legislation and regulations, and any regulatory bodies, that govern the advertising, promotion and sale of drugs and medical devices, and other life sciences products.**

The advertising, promotion and sale of life sciences products in Australia is governed by the TG Act and the TG Regulations. The TGA is the primary regulator. The TGA also issues the *Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021 (Cth) (TGAC)*, which applies to the advertisement of therapeutic goods to consumers, but not to healthcare professionals or as part of a public health campaign. Under the TGAC, “advertise” means any statement, pictorial representation or design that is intended, directly or indirectly, to promote the goods, including any labelling. In practice, this definition is applied broadly. The advertising of these products is also governed by the *Competition and Consumer Act 2010 (Cth)* including the ACL and subordinate legislation, which regulates the advertisement of consumer goods generally. The Australian Competition and Consumer Commission (ACCC) administers these instruments. Further, as described above, there are a number of industry bodies that self-regulate promotional activities for specific industry sectors, and some of these industry codes have mandatory effect as a condition of registration on the ARTG.

Prescription medicines can only be advertised to healthcare professionals. Such advertisement is regulated by the MACC and supporting guidelines. It is an offence to advertise prescription medicines to consumers. Compliance with the MACC is often a condition of a prescription medicine’s listing. The advertisement of medical devices is governed by the TGAC and MTIC (see question 1.4).

**4.2 What restrictions are there on the promotion of drugs and medical devices for indications or uses that have not been approved by the governing regulatory authority (“off-label promotion”)?**

Off-label promotion is prohibited. The TG Act imposes a general prohibition against the advertisement of therapeutic goods that have not been included in the ARTG (for that intended purpose). However, this prohibition does not apply to advertisements directed exclusively at healthcare professionals, wholesalers of therapeutic goods and purchasing officers at hospitals and certain other healthcare organisations. Any communications that are exclusive to such groups also must comply with the various industry codes that regulate interactions between medical device companies and healthcare professionals.

There is also a separate provision in the TG Act that makes it an offence to advertise a medicine (but not a medical device) for an indication that is not an approved indication on the ARTG.

The MACC allows medical company personnel to provide information on unapproved medicines or indications to healthcare professionals only in response to an unsolicited request. Companies that invite healthcare professionals to speak at a sponsored event must ensure that the professional is familiar with the product’s approved indications and with the obligation not to advertise unapproved products or indications. Companies must be able to provide documentary evidence of this briefing.

In digital medical information applications, information regarding unapproved medicines and uses may only be provided to healthcare professionals if they execute a search using specific search terms related to the medicine.

Similarly, there is nothing in the MTIC that prohibits the advertising of unapproved medical devices or uses to healthcare professionals or otherwise delivering information to healthcare professionals about pre-approval medical devices. However, any such communications to healthcare professionals must comply with the principles and requirements set out in the MTIC.

**4.3 What is the impact of the regulation of the advertising, promotion and sale of drugs and medical devices on litigation concerning life sciences products?**

The existence of self-regulation and complaints mechanisms under the industry codes means that company disputes rarely end in litigation. The ACL protects consumers from advertising that is misleading and deceptive (see question 1.2) and allows for contracts entered into as a result of the misleading advertising to be set aside, or for damages to be awarded. Liability for advertising that breaches a statutory guarantee is strict.

The TGA continues to remain active in pursuing action against companies and persons who breach the TG Act and TGAC, and there have been multiple actions in recent years that have led to significant penalties being ordered against companies and individuals for breaches of the mandatory rules for advertising of medicines, including the ban on advertising prescription-only medicines to the public and prohibitions of misleading claims, especially in connection with the unlawful advertising of nicotine vapes.

## 5 Data Privacy

**5.1 How do life sciences companies that distribute their products globally comply with data privacy standards such as GDPR and other similar standards?**

The GDPR does not have any direct application in Australia. Rather, data privacy in Australia is primarily regulated by the *Privacy Act 1988 (Cth)* (including the Australian Privacy Principles and the Notifiable Data Breaches Scheme contained in the Act), as well as certain state legislation, including legislation that deals specifically with health information.

All businesses who carry on business in Australia are required to comply with the Privacy Act. There are significant penalties for serious or repeated breaches of the Privacy Act. The Australian Information and Privacy Commissioner has powers to request and share information, including with foreign privacy authorities. In February 2023, the Australian Government released its formal response to the Privacy Act Review Report. Significant changes to the Privacy Act are likely to occur in 2024.

With regard to Australian companies operating abroad, while we are not experts in European law, we do understand that Australian life sciences companies that distribute or advertise their products in the EU are required to appoint a representative in an EU Member State, subject to a number of exceptions.

**5.2 What rules govern the confidentiality of documents produced in litigation? What, if any, restrictions are there on a company’s ability to maintain the confidentiality of documents and information produced in litigation?**

When ordered to produce documents concerning a particular issue in the litigation (via discovery or subpoena), a company must

produce all responsive documents in its possession, custody or control, save for documents subject to privilege. This includes production of confidential documents. Parties often enter into an agreement limiting access to confidential documents to certain persons (for example, lawyers and experts). However, if the documents so produced are later tendered into evidence in the litigation, it can be very difficult to maintain confidentiality over them and a Court order is required.

Parties to litigation compelled to produce documents also have the protection of the *Harman* obligation, a common law doctrine that prevents the parties, without leave of the Court, from using documents produced on compulsion for any other purpose than that for which the documents were produced, unless and until the documents are received into evidence.

### 5.3 What are the key regulatory considerations and developments in Digital Health and their impact, if any, on litigation?

The TGA regulates digital health products under its existing regulatory framework. The TG Act's definition of "medical device" applies to some digital health devices, such as diagnostic software. The TGA's regulation of medical devices, including software that is a medical device (**SaMD**), is based on the risk the device poses to patients or healthcare professionals. Similarly to other medical devices, unless excluded, SaMDs must be included on the ARTG before they can be supplied in Australia. The TGA regulations also exclude certain types of software from the medical device regime, such as consumer products directed at maintaining general health and well-being, and also clarifies the classification rules for software. The TGA has been in the process of reviewing the regulation of SaMDs in Australia to enhance safety, performance and quality of medical devices in Australia. The TGA has published guidance about the application of these rules. These rules may have an indirect effect on litigation, especially to the extent that they place certain products outside the therapeutic goods framework (meaning that they may now be treated as pure consumer products).

## 6 Clinical Trials and Compassionate Use Programmes

### 6.1 Please identify and describe the regulatory standards, guidelines, or rules that govern how clinical testing is conducted in the jurisdiction, and their impact on litigation involving injuries associated with the use of the product.

Therapeutic goods must not be supplied in Australia unless they are registered on the ARTG or are subject to an exemption. Clinical trials involving unapproved therapeutic goods (including unapproved indications) are subject to the Clinical Trial Notification (**CTN**) or the Clinical Trial Approval (**CTA**) schemes, both of which enable sponsors to obtain from the TGA an exemption from the general registration requirement.

The CTN Scheme is a notification process generally used for therapeutic goods for which there is adequate preclinical information available. The sponsor must notify the TGA of the proposed testing. The testing protocol is then reviewed by a Human Research Ethics Committee (**HREC**). Absent further action from the TGA, notification of the TGA and approval by an HREC is sufficient for an exemption to apply.

The CTA Scheme is an evaluation process and involves a review of limited, scientific data prior to the start of a trial. The process is generally used for novel treatments where there is

limited preclinical information available, or where the treatment itself is high risk. The CTA Scheme involves an application to the TGA that must receive TGA approval. If approved, the proposed trial is then reviewed by a HREC. For both the CTN or CTA Schemes, the institution or organisation at which the trial will be conducted gives the final authorisation for the conduct of the trial at the site, following approval by the reviewing HREC.

The conduct of clinical trials is also subject to certain guidelines; in particular, the *Guidance on Good Clinical Practice*, the *National Statement on Ethical Conduct in Human Research* and the *Australian Code for the Responsible Conduct of Research*. The *National Statement on Ethical Conduct in Human Research* is the national ethical standard against which all tests involving humans, including clinical tests, must be reviewed, and builds upon the *Helsinki Declaration*. The *Guidance on Good Clinical Practice* is an international ethical and scientific standard for the conduct of clinical trials, which has been adopted by the TGA with some modification.

Almost universally, HREC approval for a clinical trial will not be given unless the trial sponsor has agreed to indemnify participants in the trial, and the investigations and institution are in accordance with a standard form of indemnity.

Product liability litigation in Australia will typically involve careful scrutiny of the results of clinical trials to determine whether they included a signal that ought to have resulted in the sponsor acting differently. However, because Australia does not have a doctrine of pre-emption, less attention is paid to the regulatory consequences of clinical trial data than in some other jurisdictions.

### 6.2 Does the jurisdiction recognise liability for failure to test in certain patient populations (e.g., can a company be found negligent for failure to test in a particular patient population)?

There is very little specific law on this topic in Australia. Certainly, representing that a product is suitable for use in certain populations if the data does not support that conclusion could give rise to liability under Australian law. However, the outcome in *Vioxx* (see question 1.2) suggests that a company cannot be found negligent for failure to test for "undiscoverable" flaws in prescription medicines.

### 6.3 Does the jurisdiction permit the compassionate use of unapproved drugs or medical devices, and what requirements or regulations govern compassionate use programmes?

Yes. Australia's Special Access Scheme (**SAS**) provides for the importation or supply of unapproved therapeutic goods to an individual patient in some circumstances. The SAS is intended for exceptional clinical circumstances, considered on a case-by-case basis. Healthcare practitioners are expected to have exhausted all available treatment options on the ARTG before making an SAS application.

A healthcare practitioner may access unapproved therapeutic goods through three pathways:

- Category A is a notification pathway for seriously ill patients with life-threatening diseases. A health practitioner's decision that the use of the product is appropriate triggers an exemption. Prior approval from the TGA is not required to access the Category A pathway.
- Category B is for patients who do not fall into Category A or C. Category B applications must be reviewed and approved by the TGA.

- Category C is a notification pathway for healthcare practitioners to access certain goods that are not on the ARTG but have an established history of use for a particular indication. These therapeutic goods are then included on published legislative instruments for specific indications and types of health practitioners. Prior approval from the TGA is not required to access the Category B pathway. However, the pathway cannot be used if the product, indication and/or type of health practitioner do not match those listed in the legislative instrument.

In certain circumstances, a medical practitioner may become an authorised prescriber of a specified unapproved therapeutic good, or a class thereof, for a particular condition or class of patients in their immediate care.

#### 6.4 Are waivers of liability typically utilised with physicians and/or patients and enforced?

Waivers are sometimes used in the context of supplying unapproved goods, but are of limited utility because it is not possible to waive liability for causes of action arising under the ACL. It is more effective to provide patients with a detailed informed consent form detailing the known risks of the product as well as the risks inherent in an unapproved use, and ask patients to acknowledge that they are aware of and have accepted these risks.

#### 6.5 Is there any regulatory or other guidance companies can follow to insulate or protect themselves from liability when proceeding with such programmes?

The TGA has published guidance for health practitioners and sponsors involved in providing patients with access to unapproved therapeutic goods through the SAS (see question 6.3). The guidance published by the TGA is regularly updated but only provides health practitioners and sponsors with an overview of the scheme.

## 7 Product Recalls

#### 7.1 Please identify and describe the regulatory framework for product recalls, the standards for recall, and the involvement of any regulatory body.

Therapeutic good recalls are primarily coordinated via the specialist regulator; the TGA (see question 7.2). More generally, for consumer goods such as cosmetics, product recalls are regulated by the ACCC under the ACL. The ACL imposes duties on suppliers to notify consumers and the regulator of voluntary recalls, and gives the government the power to order compulsory product recalls in the rare case that the regulator is of the opinion that the supplier has not taken satisfactory steps in its voluntary recall action. In the absence of statutory criteria, a supplier's decision to undertake a voluntary recall is based on common law duties. A supplier's duty of care may extend to recalling products with an identifiable safety-related defect.

The ACCC issues product safety recall guidelines to assist suppliers conducting a recall in accordance with the ACL.

Statutory obligations are triggered only once a supplier initiates a recall. Suppliers must notify consumers of a recall where the product may cause injury, where it is unlikely to meet a safety standard, or where a ban is in place. The ACL requires that the government (in practice, the ACCC) be notified of any recall action within two business days of it being commenced. For certain types of products, other regulators may need to be

notified of any recall, and each regulator may impose specific recall obligations on suppliers. This information is provided by Product Safety Australia. The TGA must be notified of product recalls relating to drugs or medical devices.

#### 7.2 What, if any, differences are there between drugs and medical devices or other life sciences products in the regulatory scheme for product recalls?

The recall of therapeutic goods is coordinated by the TGA. The TGA has published a uniform recall procedure for therapeutic goods (**URPTG**), which provides a consistent approach for undertaking a recall of any therapeutic good supplied, imported into or exported from Australia. While this document is not law, in practice it is the framework for any recall action relating to therapeutic goods. It provides for early engagement with the TGA about any proposed recall action and consultation before the recall is initiated. There are four actions that sponsors of these products may take: recalls; product defect corrections (including relabelling); hazard alerts; and product defect alerts.

#### 7.3 How do product recalls affect litigation and government action concerning the product?

While a recall will increase the risk of litigation and regulatory investigation, the vast majority of recalls do not result in any follow-on action of this sort. In litigation, the publication of a product recall notice is not in itself an admission of liability, provided it does not contain words to that effect.

#### 7.4 To what extent do recalls in the United States or Europe have an impact on recall decisions and/or litigation in the jurisdiction?

Recalls of internationally distributed products in other jurisdictions may trigger a recall of those products in Australia. Australian regulators are often proactive in seeking information from local sponsors. The TGA regularly receives information about recalls of therapeutic goods overseas by agencies such as the FDA and the EMA. If a product that is the subject of an overseas recall is entered on the ARTG or has otherwise been imported and distributed in Australia, the TGA will assess whether the importer will be required to recall the products in Australia.

#### 7.5 What protections does the jurisdiction have for internal investigations or risk assessments?

There are few protections for internal investigations or risk assessments, except for a legitimate claim of privilege over the relevant material. Natural persons (but not corporations), if compelled to give evidence, may also claim privilege against self-incrimination, but this privilege does not protect that individual from a notice issued to a third party.

#### 7.6 Are there steps companies should take when conducting a product recall to protect themselves from litigation and liability?

Manufacturers owe a continuing duty to consumers to take reasonable care to prevent a defective product from causing harm. Failure to recall defective products may amount to negligence if the company is aware of the defect and a person is harmed as a result of using the product. The ACCC provides



guidance on the content of recall communications. The recall notice should include a product description, a picture of the product, a description of the defect or why the product is being recalled, a statement of the hazard and how it could lead to injuries, and a list of immediate actions the consumer should take, and should provide the contact details for assistance with accessing a refund or having the product repaired or replaced. Any recall notice should be submitted to the ACCC for comment prior to publishing. A supplier must also notify the Minister within 48 hours of initiating a recall. Failure to do so is unlawful. A supplier who fails to comply with a compulsory recall notice may be found guilty of a criminal offence. More generally, recall communications should be carefully reviewed to ensure that accurate information is provided but that admissions are not made improperly.

Suppliers of therapeutic goods should consult the URPTG for the steps involved in conducting a recall (see question 7.2).

## 8 Litigation and Dispute Resolution

### 8.1 Please describe any forms of aggregate litigation that are permitted (i.e., mass tort, class actions) and the standards for such aggregate litigation.

Class actions are available under Part IVA of the *Federal Court of Australia Act 1976* (Cth) and almost identical provisions exist in Victoria, NSW, Queensland, Western Australia and Tasmania. The procedure is substantially the same in each jurisdiction and permits a class action to be commenced if:

- there are seven or more persons who have claims;
- the claims arise out of similar or related circumstances; and
- the claims give rise to a substantial common issue of fact or law.

There is no requirement that every class member must have a claim against every defendant. Nor is there any certification requirement.

### 8.2 Are personal injury/product liability claims brought as individual plaintiff lawsuits, as class actions or otherwise?

Personal injury or product liability claims can be brought as individual lawsuits and in class actions through the mechanisms outlined in question 8.1.

### 8.3 What are the standards for claims seeking to recover for injuries as a result of use of a life sciences product? (a) Does the jurisdiction permit product liability claims? (b) Are strict liability claims recognised?

Generally, product liability claims resulting in injury will be based on negligence and breaches of the ACL. In claims based on negligence, a claimant must prove, on the balance of probabilities, that the manufacturer owed them a duty of care, that that duty of care was breached, and that the breach caused the claimant's injury. The ACL contains a number of statutory consumer guarantees relating to defective products that operate as "strict liability" provisions, and a regime for liability for "safety defects" closely modelled on the 1985 European Product Liability Directive. Claimants need only prove that, on the balance of probabilities, the product has a safety defect, that the product was not fit for purpose or was not of acceptable quality and that this caused their loss.

### 8.4 Are there any restrictions on lawyer solicitation of plaintiffs for litigation?

There are few restrictions on lawyer solicitation of plaintiffs. In NSW, the Solicitors' Conduct Rules require solicitors to ensure that any advertising of their services is not false, misleading or deceptive, offensive or otherwise prohibited by law.

In class actions, notice must be given to class members, enabling them to opt out of proceedings. Opt-out notices are generally given by way of newspaper advertisements and more recently through publication online and on social media platforms. The form of an opt-out notice must be approved by the Court, and the Court will exercise a supervisory jurisdiction over communications with group members who are not clients of the law firms in question. In the pacemaker class action proceedings of *Courtney v Medtel Pty Ltd* (2002) 122 FCR 168, the Federal Court of Australia accepted that there was nothing in the law preventing respondents from communicating with group members, provided that such communication "does not infringe any other law or ethical constraint (such as a professional conduct rule)". The same principle would presumably apply to communications to group members by plaintiffs' lawyers.

### 8.5 What forms of litigation funding are permitted/ utilised? What, if any, regulation of litigation funding exists?

Australia has an active commercial litigation funding industry. While Australian lawyers are currently prohibited from charging contingency fees (with one exception), commercial litigation funders can enter into funding agreements pursuant to which the funder agrees to pay the cost of the litigation in exchange for a percentage of any amount received by the claimants. The use of litigation funding has steadily increased since 2006 when the High Court held it was not an abuse of process, but the law in this area – especially in class actions – is fast developing.

In late 2022, the requirement (which was only introduced in 2020) for litigation funders to hold an Australian Financial Services licence was removed. Since June 2020, one Australian jurisdiction (Victoria) permits the Court to approve contingency fees arrangements for lawyers in class actions, which has seen the Victorian Supreme Court emerge as the class action forum of choice. In 2023, the Full Federal Court confirmed that the Federal Court has the power to make a common fund order when approving settlement, which requires all group members to contribute to a litigation funders' commission, regardless of whether they signed up to a funding agreement. This decision has brought greater certainty to parties and litigation funders alike. Law reform in this area remains under active consideration; Superior Courts continue to consider questions regarding the operations of litigation funders, as do government and industry reports.

### 8.6 What is the preclusive effect on subsequent cases of a finding of liability in one case? If a company is found liable in one case, is that finding considered *res judicata* in subsequent cases?

There are three related concepts in Australian law. *Res judicata* means that once a claim by one party against another is determined, the claim merges in the judgment and cannot be litigated again. *Issue estoppel* is broader and prohibits re-litigating an issue of fact or law that has been finally determined as between the parties in question. *Ansbum estoppel* is broader still, and prohibits a party from raising issues in litigation that they could and should have raised in earlier litigation.



Each of these doctrines only operates in litigation involving the same parties or persons claiming through them. They do not prevent a defendant from raising a defence to a claim by B that had been unsuccessfully raised in a claim by A.

**8.7 What are the evidentiary requirements for admissibility of steps a company takes to improve their product or correct product deficiency (subsequent remedial measures)? How is evidence of such measures utilised in litigation?**

For such evidence to be admissible, it must be relevant to a fact in issue in the proceedings, and must not be excluded by an exclusionary rule of evidence, including the opinion rule and the hearsay rule. However, the business records rule creates an exception to the hearsay rule in respect of business records that are kept by a company in the course of, or for the purpose of, its business, insofar as they contain representations made by a person with personal knowledge of the asserted facts. As a result, documents obtained on discovery that record a company's processes will usually be admitted into evidence if relevant. Plaintiffs' lawyers often rely on documents created in the context of remedial action as admissions of prior negligence or breach of relevant legal standards.

**8.8 What are the evidentiary requirements for admissibility of adverse events allegedly experienced by product users other than the plaintiff? Are such events discoverable in civil litigation?**

Life sciences companies usually keep an adverse events database, portions of which are likely to be discoverable in litigation. Further, the business records rule (discussed above) would likely enable any such database to be admitted into evidence. Whether such evidence will be given weight depends upon the issue in the litigation that it is said to be relevant.

**8.9 Depositions: What are the rules for conducting depositions of company witnesses located in the jurisdiction for use in litigation pending outside the jurisdiction? For example, are there "blocking" statutes that would prevent the deposition from being conducted in or out of the jurisdiction? Can the company produce witnesses for deposition voluntarily, and what are the strategic considerations for asking an employee to appear for deposition? Are parties required to go through the Hague Convention to obtain testimony?**

Depositions are not part of Australian litigation practice. However, there are no blocking statutes that prevent the taking of evidence in Australia for the purpose of foreign proceedings. The *Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters* is the usual mechanism to obtain such evidence. A party to foreign proceedings may ask their Court to issue a letter of request to an Australian Court. The letter of request must comply with the domestic rules of the relevant Court for taking evidence. State and Territory Supreme Courts may make an order giving effect to such letters of request. This power is discretionary, but the Australian Court will generally make an order if it is satisfied that the domestic procedural requirements were followed and the request is made for a legitimate purpose. The Court then issues a subpoena requiring the individual to attend and give evidence. Witness examination is conducted in the manner prescribed for taking evidence otherwise than in trial in the relevant Australian jurisdiction.

**8.10 How does the jurisdiction recognise and apply the attorney-client privilege in the context of litigation, and with respect to in-house counsel?**

Australia recognises and applies legal professional privilege (LPP) in litigation and regulatory investigations. Several cases have considered the application of LPP to in-house counsel. For a communication to attract LPP, it must have been made in the in-house lawyer's capacity as a lawyer, and not some other capacity, have been made for the dominant purpose of giving or receiving legal advice or for use in actual or anticipated litigation and must otherwise comply with the requirements to establish LPP.

**8.11 Are there steps companies can take to best protect the confidentiality of communications with counsel in the jurisdiction and communications with counsel outside the jurisdiction for purposes of litigation?**

In order for a communication to attract privilege under Australian law, it must be a:

- a) confidential communication between the client and the person or between a lawyer acting for the client and the other person; or
- b) confidential document that was prepared for the dominant purpose of the client being provided with legal services in relation to the litigation.

The best way to protect such communications is to ensure that they remain confidential by limiting distribution on a need-to-know basis and to make the privileged purpose of the communication clear on the face of the document.

It is also possible for privilege in a document to be waived if the document is disclosed in a way that is incompatible with the retention of confidentiality over that material. Since privilege over confidential material may be waived inadvertently, companies should be judicious about the distribution of material.

**8.12 What limitations does the jurisdiction recognise on suits against foreign defendants?**

The suit must satisfy the requirements of the rules of the relevant Court for invoking the jurisdiction of the Court, in respect of an issue outside its jurisdiction. However, since one ground to invoking such jurisdiction is that there is a tortious claim in respect of which damage has been suffered in Australia, there is seldom a question about this. The jurisdiction of the Court is not invoked until the originating process is properly served on the foreign defendant. Each jurisdiction has its own requirements for the service on foreign defendants.

**8.13 What is the impact of U.S. litigation on "follow-on" litigation in your jurisdiction?**

There is some concern for the use of documents obtained in U.S. regulatory proceedings to be used as the fruits for "follow-on" claims in Australia. Both U.S. and Australian laws permit the adverse findings in public enforcement proceedings to be used to establish the same facts in follow-on litigation. *Bray v F Hoffmann-La Roche Ltd* [2003] FCAFC 153 involved a class action that "followed on" from pecuniary penalty proceedings in Australia and the U.S. against the respondent group of companies.

**8.14 What is the likelihood of litigation evolving in your jurisdiction as a result of U.S. litigation?**

There have been many instances of "copycat" litigation, in which

class actions were brought that mirror proceedings commenced in the U.S. given the relatively developed plaintiffs' bar and low barriers to commencement of a class action in Australia.

**8.15 For EU jurisdictions, please describe the status and anticipated impact of the Collective Redress Directive and Product Liability Directive on drug and medical device litigation in your jurisdiction.**

This is not applicable for Australia.



**Greg Williams** is internationally recognised as an experienced litigation lawyer, with particular expertise providing regulatory and litigation advice to pharmaceutical and medical device companies. Greg's expertise encompasses the whole product life cycle, including registration, reimbursement, advertising disputes, and product safety and recalls. He is particularly skilled in providing strategic advice on pricing and reimbursement issues, successfully guiding clients through challenging Australian reimbursement applications. Greg also defends product liability claims and class actions, having represented several high-profile cases. Greg is also recognised by numerous directories, including *Chambers Asia-Pacific* as Band 1 for Life Sciences and by *Who's Who Legal* as a Thought Leader in Life Sciences Product Liability.

**Clayton Utz**  
1 Bligh Street  
Sydney NSW 2000  
Australia

Tel: +61 2 9353 4798  
Email: [gwilliams@claytonutz.com](mailto:gwilliams@claytonutz.com)  
LinkedIn: [www.linkedin.com/in/gregwilliamsculaw](http://www.linkedin.com/in/gregwilliamsculaw)



**Alexandra Rose** has extensive experience advising on high-stakes multi-jurisdictional class actions, product liability and regulatory matters within the pharmaceutical and medical device industries. Her specialist skillset includes expert guidance on navigating Australia's therapeutic goods and consumer products regulatory regimes, catering to leading global companies such as Bayer, Johnson & Johnson and Philips. As a product liability and class actions defence lawyer, Alex uses her commercial litigation skills to strengthen global defence strategies, enhance efficiency and ensure clients can focus on core commercial goals. Alex is recognised in guides such as *Legal 500 Asia-Pacific*, *Who's Who Legal* and *Best Lawyers*. In addition, *Global Law Experts* has recognised Alex as the: 2023 Australian: Class Actions Defense Lawyer of the Year; Product Liability Defense Lawyer of the Year; Life Sciences Industry of the Year; and Health Technology Sector Lawyer of the Year. She is also a member of the Defense Research Institute (DRI) and American Bar Association Litigation (International) Sub Committee.

**Clayton Utz**  
1 Bligh Street  
Sydney NSW 2000  
Australia

Tel: +61 2 9353 4836  
Email: [arose@claytonutz.com](mailto:arose@claytonutz.com)  
LinkedIn: [www.linkedin.com/in/alex-rose-41772285](http://www.linkedin.com/in/alex-rose-41772285)



**Ethan Tindall** is a regulatory and litigation lawyer that specialises in advising clients in the consumer, health and life sciences industries. He advises on a range of regulatory matters including product safety and recalls, registration, mandatory reporting and regulator engagement. In particular, he assists local and overseas pharmaceutical and medical device clients to navigate Australia's therapeutic goods and regulatory regimes. In a litigation context, Ethan has experience working on high-profile cases – particularly in large-scale class actions – across the medical device, pharmaceutical, automotive and consumer goods industries. Having started his career at a leading Australian pharmaceutical company, Ethan brings a commercial perspective when advising on the risks and opportunities faced by clients in ever-evolving legal, regulatory and technical landscapes.

**Clayton Utz**  
1 Bligh Street  
Sydney NSW 2000  
Australia

Tel: +61 2 9353 4279  
Email: [etindall@claytonutz.com](mailto:etindall@claytonutz.com)  
LinkedIn: [www.linkedin.com/in/ethan-tindall-02a922123](http://www.linkedin.com/in/ethan-tindall-02a922123)

Clayton Utz is a leading Australian law firm, known for the strength of its independent culture and its confident and engaging approach. With approximately 165 partners and over 1,600 employees across our six offices, we have built a reputation for innovative and incisive advice.

As a full-service commercial law firm, we have lawyers with diverse and broad-ranging legal experience, across a range of industry sectors. Our strength lies not only in the range of skills and depth of expertise held by our individual lawyers, but also in our ability to work together effectively as a full-service, national team and our ability to bring together teams of lawyers with the right mix of legal and commercial skills to match the needs of our clients.

With a genuine commitment to client service, we are trusted advisers to a diverse base of Australian and international clients. We pride ourselves on

the reputation we have built for legal innovation and excellence, driven by our goal to give our clients creative commercial solutions.

Whilst we are proudly Australian, we have a long-standing affiliation with law firms worldwide and are experienced in working with international law firms and advisers.

[www.claytonutz.com](http://www.claytonutz.com)

**CLAYTON UTZ**

# International Comparative Legal Guides

The **International Comparative Legal Guide (ICLG)** series brings key cross-border insights to legal practitioners worldwide, covering 58 practice areas.

**Drug & Medical Device Litigation 2024** features two expert analysis chapters and 17 Q&A jurisdiction chapters covering key issues, including:

- Regulatory Framework
- Manufacturing
- Transactions
- Advertising, Promotion and Sales
- Data Privacy
- Clinical Trials and Compassionate Use Programmes
- Product Recalls
- Litigation and Dispute Resolution

